Last reviewed 2026-05-19 · How we verify

Belloxa

Chonnam National University Hospital · Phase 2 active Small molecule ✓ Verified May 2026

Belloxa is a Small molecule drug developed by Chonnam National University Hospital. It is currently in Phase 2 development. Also known as: Oxaliplatin.

Belloxa is a medication studied in combination with Belotaxel for the treatment of Non-Small Cell Lung Cancer. Specifically, it is being investigated as part of a Phase II trial in combination with Docetaxel for the treatment of Stage IV or relapsed Non-Small Cell Lung Cancer.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Belloxa
Also known as	Oxaliplatin
Sponsor	Chonnam National University Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Belloxa CI brief — competitive landscape report
Belloxa updates RSS · CI watch RSS
Chonnam National University Hospital portfolio CI

Frequently asked questions about Belloxa

What is Belloxa?

Belloxa is a Small molecule drug developed by Chonnam National University Hospital.

Who makes Belloxa?

Belloxa is developed by Chonnam National University Hospital (see full Chonnam National University Hospital pipeline at /company/chonnam-national-university-hospital).

Is Belloxa also known as anything else?

Belloxa is also known as Oxaliplatin.

What development phase is Belloxa in?

Belloxa is in Phase 2.

Manufacturer: Chonnam National University Hospital — full pipeline
Therapeutic area: All drugs in Other
Also known as: Oxaliplatin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing